EP3177321

TUMOR ANTIGEN SPECIFIC ANTIBODIES AND TLR3 STIMULATION TO ENHANCE THE PERFORMANCE OF CHECKPOINT INTERFERENCE THERAPY OF CANCER

  • Status:
    EP einkaleyfi: Þýðing ekki lögð inn
  • EP appl. date:
    7.8.2015
  • EP published:
    25.11.2020
  • EP application number:
    15829910.7
  • Max expiry date:
    6.8.2035
  • Title:
    TUMOR ANTIGEN SPECIFIC ANTIBODIES AND TLR3 STIMULATION TO ENHANCE THE PERFORMANCE OF CHECKPOINT INTERFERENCE THERAPY OF CANCER

Timeline

Today
7.8.2015EP application
25.11.2020EP Publication

Owner

  • Name:
    Oncoquest Pharmaceuticals Inc.
  • Address:
    670-21 Sannae-ro, Sannae-myeon, Miryang-Si, KR

Inventor

  • Name:
    MADIYALAKAN, Ragupathy
  • Address:
    Edmonton, Alberta T6E 2S1, CA
  • Name:
    NICODEMUS, Christopher F.
  • Address:
    Charlestown, Massachusetts 02129, US

Priority

  • Number:
    201462034915 P
  • Date:
    8.8.2014
  • Country:
    US

Classification

  • Categories:
    A61K 39/395, A61K 39/39, A61P 35/00, A61P 37/02

Upload documents